Therapeutic area
Kidney and urology
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.govMethods & limitations
Approvals since 2023
44
Originals, plus breakthrough or accelerated new uses
Recruiting Phase 2
34
Industry-sponsored
Recruiting Phase 3
29
Industry-sponsored
Recruiting Phase 4 (post-approval)
3
Industry-sponsored
Recent approvals
- Trutakna (Atacicept-Vymj) · Vera Therapeutics Inc. NovelPriority reviewJul 7, 2026
To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk for disease progression
- Utebzi (Tebipenem Pivoxil Hydrobromide) · Glaxosmithkline NovelPriority reviewJun 17, 2026
To treat complicated urinary tract infections, including pyelonephritis, caused by several susceptible microorganisms in adults who have limited or no alternative oral treatment options
- Zaynich (Cefepime Hydrochloride, Zidebactam) · Wockhardt Bio AG NovelPriority reviewMay 29, 2026
To treat complicated urinary tract infections, including pyelonephritis, caused by designated susceptible microorganisms
- Epinephrine (Epinephrine) · Baxter Hlthcare Corp Mar 30, 2026
- Flavalta (Epinephrine Bitartrate, Lidocaine Hydrochloride) · Deproco Mar 19, 2026
- Oziltus (Denosumab-Mobz) · Amneal Pharms LLC Dec 19, 2025
- Boncresa (Denosumab-Mobz) · Amneal Pharms LLC Dec 19, 2025
- Lerochol (Lerodalcibep-Liga) · Lib Therapeutics, Inc. NovelDec 12, 2025
To reduce low-density lipoprotein cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia, as an adjunct to diet and exercise
- Imfinzi (Durvalumab) · Astrazeneca Uk LTD Breakthrough therapyPriority reviewOrphanNov 25, 2025
- Voyxact (Sibeprenlimab-Szsi) · Otsuka Pharm CO LTD NovelBreakthrough therapyAccelerated approvalPriority reviewNov 25, 2025
To reduce proteinuria in primary immunoglobulin A nephropathy in adults at risk for disease progression
- Conexxence (Denosumab-Bnht) · Fresenius Kabi USA LLC Oct 29, 2025
- Osenvelt (Denosumab-Bmwo) · Celltrion INC Oct 29, 2025
- Denosumab-Dssb (Denosumab-Dssb) · Samsung Bioepis CO LTD Oct 29, 2025
- Aukelso (Denosumab-Kyqq) · Biocon Biologics INC Oct 29, 2025
- Osvyrti (Denosumab-Desu) · Accord Biopharma Inc. Oct 29, 2025
Recruiting trials by phase
Industry-sponsored drug and biologic trials.
Most approvals since then, by company
- GSK3
Drugs in development
Investigational drugs in Phase 2 and 3 trials for conditions in this area, most trials first.
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- CadonilimabAK104Phase 331 trials
Akeso · Hepatocellular Carcinoma, Gastric / Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- AdabelimumabSHR-A2102, SHR2554Phase 320 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- IanalumabVAY736, VAY736 AIPhase 318 trials
Novartis · Primary Immune Thrombocytopenia (ITP), Systemic Lupus Erythematosus, Sjogren Syndrome
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- VolrustomigMEDI5752Phase 313 trials
AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer
- 9MW2821Phase 311 trials
Mabwell (Shanghai) Bioscience Co., Ltd. · Urothelial Carcinoma, Advanced Urothelial Carcinoma, Locally Advanced or Metastatic Triple-negative Breast Cancer
- Savolitinibhmpl-504, AZD6094Phase 311 trials
AstraZeneca · Carcinoma, Non-small Cell Lung Cancer, Non-Small Cell Lung Cancer
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- ZanzalintinibXL092Phase 311 trials
Exelixis · Colorectal Cancer, Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
- Intismeran autogeneV940, mRNA-4157Phase 310 trials
Merck & Co. · Non-small Cell Lung Cancer, Melanoma, Bladder Cancer
Largest recruiting Phase 3 trials
- A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)Pivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07241390 · 7,140 participants (planned) · Start Dec 1, 2025 · Primary completion Aug 2031
Drug: Orforglipron; Placebo · For: Atherosclerosis Cardiovascular Disease; Chronic Kidney Disease
Sites: Bahía Blanca, Argentina; Buenos Aires, Argentina; C.a.b.a., Argentina · 566 sites in all
- A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.Pivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07753993 · 7,000 participants (planned) · Start Aug 21, 2026 · Primary completion Oct 4, 2030
Drug: Elecoglipron; Placebo · For: Chronic Kidney Disease
Sites: Huntsville, Alabama; Montgomery, Alabama; Sheffield, Alabama · 715 sites in all
- A Phase III Clinical Study on the Efficacy and Safety of HRS-1780 in the Treatment of Patients With Chronic Kidney DiseasePivotal-lookingRecruiting
Shandong Suncadia Medicine Co., Ltd.Industry
NCT07419828 · 5,386 participants (planned) · Start Mar 13, 2026 · Primary completion Apr 2030
Drug: HRS-1780 tablets; Placebo · For: Chronic Kidney Disease
Sites: Nanjing, China
- A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood PressurePivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06742723 · 5,000 participants (planned) · Start Mar 3, 2025 · Primary completion Dec 18, 2029
Drug: Baxdrostat/dapagliflozin; Placebo/dapagliflozin · For: Chronic Kidney Disease and Hypertension
Sites: Fairhope, Alabama; Sun City, Arizona; Tucson, Arizona · 771 sites in all
- A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)Pivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07624305 · 2,800 participants (planned) · Start Sep 1, 2026 · Primary completion Jul 1, 2030
Drug: Balcinrenone/dapagliflozin; Dapagliflozin and 2 more · For: Renal Insufficiency, Chronic
Sites: Huntsville, Alabama; Surprise, Arizona; Tempe, Arizona · 478 sites in all
- A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background DapagliflozinPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07662135 · 900 participants (planned) · Start Jul 6, 2026 · Primary completion Jul 13, 2028
Drug: Elecoglipron; Placebo · For: Type 2 Diabetes Mellitus; Type 2 Diabetes With Chronic Kidney Disease
Sites: Sun City, Arizona; Surprise, Arizona; Concord, California · 186 sites in all
- A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA NephropathyPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT04557462 · 540 participants (planned) · Start Sep 20, 2021 · Primary completion Dec 4, 2030
Drug: LNP023 · For: Primary IgA Nephropathy
Sites: Glendale, Arizona; San Diego, California; San Dimas, California · 161 sites in all
- A Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A NephropathyPivotal-lookingRecruiting
Jade Biosciences, Inc.Industry
NCT07902817 · 480 participants (planned) · Start Dec 2026 · Primary completion Jun 2029
Drug: JADE101; Placebo · For: IgA Nephropathy (IgAN)
Sites: Arvada, Colorado; Lauderdale Lakes, Florida; Atlanta, Georgia · 4 sites in all
- A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)Pivotal-lookingRecruiting
BiogenBiogen (BIIB)
NCT06935357 · 454 participants (planned) · Start May 8, 2025 · Primary completion May 31, 2027
Drug: Felzartamab; Placebo · For: Immunoglobulin A Nephropathy (IgAN)
Sites: Little Rock, Arkansas; Apple Valley, California; Carlsbad, California · 265 sites in all
- A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on DialysisPivotal-lookingRecruiting
Genexine, Inc.Industry
NCT06466785 · 429 participants (planned) · Start Jan 25, 2024 · Primary completion Jun 2027
Drug: Efepoetin Alfa; Darbepoetin Alfa · For: Anemia of Chronic Kidney Disease
Sites: Yerevan, Armenia; Blagoevgrad, Bulgaria; Dobrich, Bulgaria · 58 sites in all
More: Kidney and urology news · literature
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.